Neurofeedback for Mild Cognitive Impairment
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a brain-training program called neurofeedback can slow the progression from mild cognitive impairment (MCI) to Alzheimer's disease. Participants will engage in a computer-based activity designed to improve brain function in areas linked to memory and learning. The trial includes two groups: one will receive active neurofeedback training, while the other will receive a placebo version with random changes. Ideal candidates for this trial are those diagnosed with MCI, living independently, and able to understand and consent to participate. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to new ways to manage MCI.
Will I have to stop taking my current medications?
The trial requires that you stop taking medications likely to affect cognitive function, such as donepezil and memantine. Other medications are not excluded, but their effects will be examined during the study.
What prior data suggests that neurofeedback is safe for individuals with mild cognitive impairment?
Research has shown that neurofeedback is generally well-tolerated, even by those with mild cognitive impairment (MCI). Studies have explored neurofeedback as a non-invasive method to improve memory and brain function. Participants in these studies did not report significant negative effects.
One study found that neurofeedback training enhanced memory in both healthy older adults and those with MCI. This technique involves altering brain activity using visual or sound cues, a safe method without serious side effects.
Overall, while more research is needed, current evidence suggests that neurofeedback is a safe option for managing memory issues related to MCI.12345Why are researchers excited about this trial?
Researchers are excited about neurofeedback as a treatment for mild cognitive impairment because it offers a novel, non-invasive approach that taps into the brain's own activity. Unlike current medications that often focus on enhancing neurotransmitter function, neurofeedback involves training individuals to regulate their brainwave patterns, specifically targeting gamma oscillatory activity. This personalized method could potentially improve cognitive function by harnessing the brain's natural plasticity, making it a promising alternative or complement to traditional treatments.
What evidence suggests that neurofeedback is effective for mild cognitive impairment?
Research has shown that neurofeedback training can enhance memory and thinking skills in people with mild cognitive impairment (MCI). In this trial, participants will join different treatment arms. The active treatment arm focuses on training participants to control specific brain activities, such as gamma waves, using a computer program. Studies have demonstrated that this training boosts memory in both healthy individuals and those with MCI. Early results suggest that neurofeedback might offer a promising and affordable method to slow memory loss in MCI, potentially preventing progression to Alzheimer's disease.23456
Are You a Good Fit for This Trial?
This trial is for individuals living independently with mild cognitive impairment (MCI), who can read English and consent to participate. It's not suitable for those with frontal temporal dementia, brain cancer, or recent stroke; people taking certain cognitive-affecting drugs like donepezil; or those with a history of significant head injury, seizures, or active substance abuse within the last year.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive gamma-neurofeedback (G-NFB) or placebo-NFB during 30-45 minute sessions twice per week for 12 weeks
Follow-up
Participants are monitored for durability of gamma band response and working memory accuracy after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Neurofeedback
Neurofeedback is already approved in United States, European Union, Canada for the following indications:
- Chronic low back pain
- Fibromyalgia
- Neuropathic pain
- Chronic pain
- Fibromyalgia
- Neuropathic pain
- Chronic pain
- Fibromyalgia
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Diego
Lead Sponsor